Monocyte-macrophage differentiation of acute myeloid leukemia cell lines by small molecules identified through interrogation of the connectivity map database

Cell Cycle

Volumn 14, Issue 16, 2015, Pages 2578-2589

  Manzotti, Gloria ^a   Parenti, Sandra ^a   Ferrari Amorotti, Giovanna ^a   Soliera, Angela Rachele ^a   Cattelani, Sara ^a   Montanari, Monica ^a   Cavalli, Daniel ^a   Ertel, Adam ^b   Grande, Alexis ^a   Calabretta, Bruno ^a,b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cell cycle; Differentiationm; Leukemia; Therapy; Transcription factor

Indexed keywords

AMANTADINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD14 ANTIGEN; CD15 ANTIGEN; COLECALCIFEROL; DIFFERENTIATION ANTIGEN; DIPERODON; FENCLONINE; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; MESSENGER RNA; RETINOIC ACID; VITAMIN D RECEPTOR; ANTINEOPLASTIC AGENT; CALCITRIOL RECEPTOR; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LEUKOCYTE ANTIGEN; PIPERIDINE DERIVATIVE; TAMOXIFEN;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BIOLOGICAL ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONNECTOME; CONTROLLED STUDY; CYTOKINESIS; DRUG REPOSITIONING; GENE EXPRESSION; GENE TARGETING; GRANULOCYTE; HL 60 CELL LINE; LEUKEMIA CELL LINE; MONOCYTE MACROPHAGE PRECURSOR CELL; MYELOID PROGENITOR CELL; PROTEIN TARGETING; UPREGULATION; ACUTE MYELOID LEUKEMIA; CELL CYCLE; DRUG EFFECTS; GENETICS; HL-60 CELL LINE; HUMAN; K-562 CELL LINE; MACROPHAGE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN PROTEIN INTERACTION;

AMANTADINE; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CCAAT-ENHANCER-BINDING PROTEINS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION; HL-60 CELLS; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; MACROPHAGES; PIPERIDINES; PROTEIN INTERACTION MAPS; RECEPTORS, CALCITRIOL; TAMOXIFEN; TRETINOIN;

EID: 84943775569     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1033591     Document Type: Article

References (50)

1. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-62; PMID: 10502596; http://dx. doi. org/10. 1056/NEJM199909303411407.
2. Dash A, Gilliland DG. Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 49-64; PMID: 11355923; http://dx. doi. org/10. 1053/beha. 2000. 0115.
3. Gilliland DG. Hematologic malignancies. Curr Opin Hematol 2001; 8: 189-91; PMID: 11561153; http://dx. doi. org/10. 1097/00062752-200107000-00001.
4. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003; 3: 89-101; PMID: 12563308; http://dx. doi. org/10. 1038/nrc989.
5. Koschmieder S, Rosenbauer F, Steidl U, Owens BM, Tenen DG. Role of transcription factors C/EBPalpha and PU. 1 in normal hematopoiesis and in leukemia. Int J Hematol 2005; 81: 368-71; PMID: 16158816; http://dx. doi. org/10. 1532/IJH97. 05051.
6. Nerlov C. C1487; EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer 2004; 4: 394-400; PMID: 15122210; http://dx. doi. org/10. 1038/nrc1363.
7. Kirstetter P, Schuster MB, Bereshchenko O, Moore S, Dvinge H, Kurz E, Theilgaard-Monch K, Mansson R, Pedersen TA, Pabst T. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemiainitiating cells. Cancer Cell 2008; 13: 299-310; PMID: 18394553; http://dx. doi. org/10. 1016/j. ccr. 2008. 02. 008.
8. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I. Fusion proteins of the retinoic acid receptoralpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815-8; PMID: 9486655; http://dx. doi. org/10. 1038/35901.
9. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, Hiddeman W, Zhang DE, Tenen DG. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8; 21) myeloid leukemia. Nat Med 2001; 7: 444-51; PMID: 11283671; http://dx. doi. org/10. 1038/86515.
10. Helbling D, Mueller BU, Timchenko NA, Hagemeijer A, Jotterand M, Meyer-Monard S, Lister A, Rowley JD, Huegli B, Fey MF, et al. The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin. Proc Natl Acad Sci U S A 2004; 101: 13312-7; PMID: 15326310; http://dx. doi. org/10. 1073/pnas. 0404731101.
11. Zhou Y, DuW, Koretsky T, Bagby GC, Pang Q. TATmediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice. Blood 2008; 112: 2474-83; PMID: 18574026; http://dx. doi. org/10. 1182/blood-2007-12-130211.
12. Liu X, Wang Y, Nakamura K, Kubo A, Hnatowich DJ. Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery. Cancer Gene Ther 2008; 15: 126-32; PMID: 18084241; http://dx. doi. org/10. 1038/sj. cgt. 7701111.
13. Fujiki A, Imamura T, Sakamoto K, Kawashima S, Yoshida H, Hirashima Y, Miyachi M, Yagyu S, Nakatani T, Sugiota K, et al. All-trans retinoic acid combined with 5-aza-20-deoxycitidine induces C/EBPa expression and growth inhibition in MLL-AF9-positive leukemic cells. Biochem Biophys Res Commun 2012; 428: 216-23; PMID: 23063977; http://dx. doi. org/10. 1016/j. bbrc. 2012. 09. 131.
14. Iijima K, Honma Y, Niitsu N. Granulocytic differentiation of leukemic cells with t(9; 11)(p22; q23) induced by all-trans-retinoic acid. Leuk Lymphoma 2004; 45: 1017-24; PMID: 15291362; http://dx. doi. org/10. 1080/1042819031000163887.
15. Gu ZM, Wu YL, Zhou MY, Liu CX, Xu HZ, Yan H, Zhao Y, Huang Y, Sun HD, Chen GQ. Pharicin B stabilizes retinoic acid receptor-a and presents synergistic differentiation induction with ATRA in myeloid leukemic cells. Blood 2010; 116: 5289-97; PMID: 20739655; http://dx. doi. org/10. 1182/blood-2010-02-267963.
16. Fang Y, Zhou X, Lin M, Ying M, Luo P, Zhu D, Lou J, Yang B, He Q. Inhibition of all-trans-retinoic acidinduced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells. Mol Carcinog 2011; 50: 24-35; PMID: 20945414; http://dx. doi. org/10. 1002/mc. 20687.
17. Cassinat B, Zassadowski F, Ferry C, Llopis L, Bruck N, Lainey E, Duong V, Cras A, Despouy G, Chourbagi D. New role for granulocyte colony-stimulating factorinduced extracellular signal-regulated kinase 1/2 in histone modification and retinoic acid receptor a recruitment to gene promoters: relevance to acute promyelocytic leukemia cell differentiation. Mol Cell Biol 2011; 31: 1409-18; PMID: 21262770; http://dx. doi. org/10. 1128/MCB. 00756-10.
18. Glasow A, Barrett A, Petrie K, Gupta R, Boix-Chornet M, Zhou DC, Grimwade D, Gallagher R, von Lindern M, Waxman S. DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia. Blood 2008; 111: 2374-7; PMID: 17993618; http://dx. doi. org/10. 1182/blood-2007-05-088344.
19. Glasow A, Prodromou N, Xu K, von Lindern M, Zelent A. Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. Blood 2005; 105: 341-9; PMID: 15339853; http://dx. doi. org/10. 1182/blood-2004-03-1074.
20. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Brunet JP, Subramanian A, Ross KN, Reich M. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-35; PMID: 17008526; http://dx. doi. org/10. 1126/science. 1132939.
21. Iorio F, Tagliaferri R, di Bernardo D. Identifying network of drug mode of action by gene expression profiling. J Comput Biol 2009; 16(2): 241-51; PMID: 19183001; http://dx. doi. org/10. 1089/cmb. 2008. 10TT.
22. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, Murino L, Tagliaferri R, Brunetti-Pierri N, Isacchi A, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 2010; 107: 14621-6; PMID: 20679242; http://dx. doi. org/10. 1073/pnas. 1000138107.
23. Zhang SD, Gant TW. sscMap: an extensible Java application for connecting small-molecule drugs using geneexpression signatures. BMC Bioinformatics 2009; 10: 236; PMID: 19646231; http://dx. doi. org/10. 1186/1471-2105-10-236.
24. McArt DG, Bankhead P, Dunne PD, Salto-Tellez M, Hamilton P, Zhang SD. cudaMap: a GPU accelerated program for gene expression connectivity mapping. BMC Bioinform 2013; 14: 305; PMID: 24112435; http://dx. doi. org/10. 1186/1471-2105-14-305.
25. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2: 151-63; PMID: 12589032.
26. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10: 331-42; PMID: 17010674; http://dx. doi. org/10. 1016/j. ccr. 2006. 09. 006.
27. Gheeya J, Johansson P, Chen QR, Dexheimer T, Metaferia B, Song YK, Wei JS, He J, Pommier Y, Khan J. Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor. Cancer Lett 2010; 293: 124-31; PMID: 20133050; http://dx. doi. org/10. 1016/j. canlet. 2010. 01. 004.
28. D'Arcy P, Brnjic S, Olofsson MH, Fryknäs M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R, Linder S. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med 2011; 17: 1636-40; PMID: 22057347; http://dx. doi. org/10. 1038/nm. 2536.
29. Kunkel SD, Suneja M, Ebert SM, Bongers KS, Fox DK, Malmberg SE, Alipour F, Shields RK, Adams CM. mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab 2011; 13: 627-38; PMID: 21641545; http://dx. doi. org/10. 1016/j. cmet. 2011. 03. 020.
30. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang A, Morgan AA, Sarwal MM, Pasrucha PJ, Butte AJ. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 2011; 3: 96ra76; PMID: 21849664; http://dx. doi. org/10. 1126/scitranslmed. 3002648.
31. Huang L, Zhao S, Frasor JM, Dai Y. An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors. PloS One 2011; 6: e22274; PMID: 21789246; http://dx. doi. org/10. 1371/journal. pone. 0022274.
32. Chen MH, Yang WL, Lin KT, Liu CH, Liu YW, Huang KW, Chang PM, Lai JM, Hsu CN, Chao KM, et al. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. PloS One 2011; 6: e27186; PMID: 22087264; http://dx. doi. org/10. 1371/journal. pone. 0027186.
33. Ferrari-Amorotti G, Mariani SA, Novi C, Cattelani S, Pecorari L, Corradini F, Soliera AR, Manzotti G, Fragliasso V, Zhang Y, et al. The biological effects of C/EBPalpha in K562 cells depend on the potency of the N-terminal regulatory region, not on specificity of the DNA binding domain. J Biol Chem 2010; 285: 30837-50; PMID: 20659895; http://dx. doi. org/10. 1074/jbc. M110. 128272.
34. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LS, Whang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-72; PMID: 3165295.
35. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704-9; PMID: 2224119.
36. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol 2006; 13: 563-7; PMID: 16793513; http://dx. doi. org/10. 1016/j. chembiol. 2006. 05. 004.
37. Ferrari-Amorotti G, Fragliasso V, Esteki R, Prudente Z, Soliera AR, Cattelani S, Manzotti G, Grisendi G, Dominici M, Pieraccioli M, et al. Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion. Cancer Res 2013; 73: 235-45; PMID: 23054398; http://dx. doi. org/10. 1158/0008-5472. CAN-12-1739.
38. Gemelli C, Martello A, Montanari M, Zanocco-Marani T, Salsi V, Zappavigna V, Parenti S, Vignudelli T, Selmi T, Ferrari S, Grande A. The Orosomucoid 1 protein is involved in the vitamin D-mediated macrophage de-activation process. Exp Cell Res 2013; 319: 3201-13; PMID: 23973664; http://dx. doi. org/10. 1016/j. yexcr. 2013. 08. 017.
39. Tavor S, Park DJ, Gery S, Vuong PT, Gombart AF, Koeffler HP. Restoration of C/EBPalpha expression in a BCR-ABLC cell line induces terminal granulocytic differentiation. J Biol Chem 2003; 278: 52651-9; PMID: 14517214; http://dx. doi. org/10. 1074/jbc. M307077200.
40. Ferrari-Amorotti G, Keeshan K, Zattoni M, Guerzoni C, Iotti G, Cattelani S, Donato NJ, Calabretta B. Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha. Blood 2006; 108: 1353-62; PMID: 16670262; http://dx. doi. org/10. 1182/blood-2006-01-011833.
41. Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 2012; 18: 605-11; PMID: 22406747; http://dx. doi. org/10. 1038/nm. 2661.
42. Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 2005; 25: 3317-22; http://dx. doi. org/10. 1523/JNEUROSCI. 4262-04. 2005.
43. Forchap SL, Pirmohamed M, Clark RE. Release of intracellular calcium primes chronic myeloid leukaemia for tyrosine kinase inhibitor-induced apoptosis. Leukemia 2012; 26: 490-8; PMID: 21886172; http://dx. doi. org/10. 1038/leu. 2011. 231.
44. Komura T, Sakai Y, Honda M, Takamura T, Wada T, Kaneko S. ER stress-induced impaired TLR signalling and macrophage differentiation of human monocytes. Cell Immunol 2013; 282: 44-52; PMID: 23665674; http://dx. doi. org/10. 1016/j. cellimm. 2013. 04. 006.
45. Issa LL, Leong GM, Eisman JA. Molecular mechanism of vitamin D receptor action. Inflamm Res 1998; 47: 451-75; PMID: 9892040; http://dx. doi. org/10. 1007/s000110050360.
46. Manfredini R, Trevisan F, Grande A, Tagliafico E, Montanari M, Lemoli R, Visani G, Tura S, Ferrari S, Ferrari S. Induction of a functional vitamin d receptor in all-trans-retinoic acid-induced monocytic differentiation of M2-type leukemic blast cells. Cancer Res 1999; 59: 3803-11; PMID: 10446999.
47. Jurutka PW, Bartik L, Whitfield GK, Mathern DR, Barthel TK, Gurerich M, Hsieh J-C, Kaczmarska M, Haussler CA, Haussler MR. Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J Bone Miner Res 2007; 22(supplement 2): V1-V10.
48. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 2005; 102: 15545-50; PMID: 16199517; http://dx. doi. org/10. 1073/pnas. 0506580102.
49. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 1991; 139: 271-9http://dx. doi. org/10. 1016/0022-1759(91)90198-O.
50. Parenti S, Ferrarini F, Zini R, Montanari M, Losi L, Canovi B, Ferrari S, Grande A. Mesalazine inhibits the beta-catenin signalling pathway acting through the upregulation of mu-protocadherin gene in colo-rectal cancer cells. Aliment Pharmacol Ther 2010; 1: 108-19; http://dx. doi. org/10. 1111/j. 1365-2036. 2009. 04149. x.